Journal of International Oncology››2024,Vol. 51››Issue (4): 249-253.doi:10.3760/cma.j.cn371439-20230908-00042
Previous ArticlesNext Articles
Received:2023-09-08Revised:2023-10-24Online:2024-04-08Published:2024-05-10
"
"
"
"
| [1] | Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management[J].Nat Rev Gastroenterol Hepatol,2020,17(9): 557-588. DOI:10.1038/s41575-020-0310-z. pmid:32606456 |
| [2] | Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors[J].Liver Int,2019,39 Suppl 1: 19-31. DOI:10.1111/liv.14095. pmid:30851228 |
| [3] | Torre LA, Siegel RL, Islami F, et al. Worldwide burden of and trends in mortality from gallbladder and other biliary tract cancers[J].Clin Gastroenterol Hepatol,2018,16(3): 427-437. DOI:10.1016/j.cgh.2017.08.017. |
| [4] | Razumilava N, Gores GJ. Cholangiocarcinoma[J].Lancet,2014,383(9935): 2168-2179. DOI:10.1016/s0140-6736(13)61903-0. pmid:24581682 |
| [5] | Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma—evolving concepts and therapeutic strategies[J].Nat Rev Clin Oncol,2018,15(2): 95-111. DOI:10.1038/nrclinonc.2017.157. |
| [6] | El-diwany R, Pawlik TM, Ejaz A. Intrahepatic cholangiocarcinoma[J].Surg Oncol Clin N Am,2019,28(4): 587-599. DOI:10.1016/j.soc.2019.06.002. pmid:31472907 |
| [7] | Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J].N Engl J Med,2010,362(14): 1273-1281. DOI:10.1056/NEJMoa0908721. |
| [8] | Lowery MA, Ptashkin R, Jordan E, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention[J].Clin Cancer Res,2018,24(17): 4154-4161. DOI:10.1158/1078-0432.CCR-18-0078. pmid:29848569 |
| [9] | Yoshikawa D, Ojima H, Iwasaki M, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma[J].Br J Cancer,2008,98(2): 418-425. DOI:10.1038/sj.bjc.6604129. |
| [10] | Sha M, Jeong S, Chen XS, et al. Expression of VEGFR-3 in intrahepatic cholangiocarcinoma correlates with unfavorable prognosis through lymphangiogenesis[J].Int J Biol Sci,2018,14(10): 1333-1342. DOI:10.7150/ijbs.26045. pmid:30123080 |
| [11] | Sang H, Li T, Li H, et al. Gab1 regulates proliferation and migration through the PI3K/Akt signaling pathway in intrahepatic cholangiocarcinoma[J].Tumour Biol,2015,36(11): 8367-8377. DOI:10.1007/s13277-015-3590-0. |
| [12] | Perez-Moreno P, Brambilla E, Thomas R, et al. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities[J].Clin Cancer Res,2012,18(9): 2443-2451. DOI:10. 1158/1078-0432.CCR-11-2370. pmid:22407829 |
| [13] | Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer[J].Clin Cancer Res,2012,18(7): 1855-1862. DOI:10.1158/1078-0432.CCR-11-0699. pmid:22388515 |
| [14] | Peng H, Zhang Q, Li J, et al. Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma[J].Oncotarget,2016,7(13): 17220-17229. DOI:10.18632/oncotarget.7948. pmid:26967384 |
| [15] | Peng M, Li H, Cao H, et al. Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma[J].J Gastroenterol,2023,58(9): 908-924. DOI:10.1007/s00535-023-02012-8. pmid:37433897 |
| [16] | Sia D, Losic B, Moeini A, et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma[J].Nat Commun,2015,6: 6087. DOI:10.1038/ncomms7087. pmid:25608663 |
| [17] | Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma[J].Hepatology,2014,59(4): 1427-1434. DOI:10.1002/hep.26890. pmid:24122810 |
| [18] | Xu J, Bai Y, Sun H, et al. A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer[J].Cancer,2021,127(21): 3975-3984. DOI:10.1002/cncr.33803. pmid:34355801 |
| [19] | Demols A, Borbath I, Van den Eynde M, et al. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase Ⅱ trial[J].Ann Oncol,2020,31(9): 1169-1177. DOI:10.1016/j.annonc.2020.05.018. pmid:32464280 |
| [20] | Bengala C, Bertolini F, Malavasi N, et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase Ⅱ trial[J].Br J Cancer,2010,102(1): 68-72. DOI:10.1038/sj.bjc.6605458. |
| [21] | Yi JH, Thongprasert S, Lee J, et al. A phase Ⅱ study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study[J].Eur J Cancer,2011,48(2): 196-201. DOI:10.1016/j.ejca.2011.11.017. |
| [22] | Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma[J].N Engl J Med,2023,388(3): 228-239. DOI:10.1056/NEJMoa2206834. |
| [23] | Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study[J].Lancet Oncol,2020,21(5): 671-684. DOI:10.1016/S1470-2045(20)30109-1. pmid:32203698 |
| [24] | Mazzaferro V, El-Rayes BF, Droz Dit Busset M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma[J].Br J Cancer,2019,120(2): 165-171. DOI:10.1038/s41416-018-0334-0. |
| [25] | Pant S, Schuler MH, Iyer G, et al. Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase 2 open-label, single-arm RAGNAR trial: expansion cohort results[J].J Clin Oncol,2023,41(4_suppl): 610. DOI:10.1200/JCO.2023.41.4_suppl.610. |
| [26] | Javle M, Roychowdhury S, Kelley RK, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study[J].Lancet Gastroenterol Hepatol,2021,6(10): 803-815. DOI:10.1016/S2468-1253(21)00196-5. |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
